Kuros Biosciences (KURN) Q3 2026 TU earnings summary

Executive summary

• 9M 2026 medical device sales rose 40% YoY to $141.8m; FY 2026 guidance raised to 36%–40% sales growth and adjusted EBITDA margin above 14.5%.

• Adjusted EBITDA increased 68% to $20.6m, with margin expanding to 14.5%; cash was $19.6m, ahead of plan.

Financial highlights

• Total Group EBITDA rose 81% YoY to $13.5m in 9M 2026, from $7.4m.

• Adjusted EBITDA increased 68% YoY to $20.6m, versus $12.2m; adjusted margin was 14.5%, up from 12.1%.

• Cash position was $19.6m, up from $9.7m at June 30, 2026, and ahead of plan.

Outlook and guidance

• FY 2026 sales growth guidance raised to 36%–40%; adjusted EBITDA margin expected to exceed 14.5%.